{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:16:58Z","timestamp":1788542218047,"version":"build-2803163510"},"reference-count":14,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T00:00:00Z","timestamp":1584576000000},"content-version":"unspecified","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Neurol Open"],"accepted":{"date-parts":[[2020,3,1]]},"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>There are increasing reports of myasthenia gravis (MG) following oncological treatment with immune checkpoint inhibitors (ICIs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>A 66-year-old man with stage 3A lung adenocarcinoma was treated with second weekly infusions of durvalumab, a programmed cell death ligand-1 inhibitor, at a dose of 10\u2009mg\/kg. After the fourth infusion, he developed diplopia, dyspnoea and constitutional symptoms including headache, weakness and anorexia. 1\u2009month later, he developed dysphagia and dysphonia. Examination showed proximal limb weakness with fatigability. An ice pack test was positive. Blood tests revealed a raised creatine kinase and positive PM-Scl75 antibody. Antititin antibody was strongly positive in the serum and cerebrospinal fluid. Antibodies for acetylcholinesterase receptor and antimuscle-specific kinase were negative. Electromyography showed myopathic changes. The patient was treated with steroids, pyridostigmine, mycophenolate mofetil and intravenous immunoglobulin. Eight weeks after treatment initiation ptosis, eye movements and limb strength were markedly improved and repeat creatine kinase was normal.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Clinicians using ICIs should have a high index of suspicion for ICI-induced MG and concurrent myositis as disease can be severe and is associated with high mortality rates.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjno-2019-000028","type":"journal-article","created":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T13:31:50Z","timestamp":1592227910000},"page":"e000028","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Myasthenia gravis and concurrent myositis following PD-L1 checkpoint inhibitor for non-small cell lung cancer"],"prefix":"10.1136","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9129-3918","authenticated-orcid":false,"given":"Chun Seng","family":"Phua","sequence":"first","affiliation":[{"name":"Department of Neurophysiology, Liverpool Hospital, Liverpool, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Murad","sequence":"additional","affiliation":[{"name":"Department of Immunology, Liverpool Hospital, Liverpool, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Fraser","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Liverpool Hospital, Liverpool, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Bray","sequence":"additional","affiliation":[{"name":"Department of Oncology, Liverpool Hospital, Liverpool, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Cappelen-Smith","sequence":"additional","affiliation":[{"name":"Department of Neurophysiology, Liverpool Hospital, Liverpool, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,3,19]]},"reference":[{"key":"2025072811472653000_2.1.e000028.1","doi-asserted-by":"crossref","DOI":"10.1007\/s11910-018-0810-1","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: diagnosis and management","volume":"18","author":"Astaras","year":"2018","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2025072811472653000_2.1.e000028.2","first-page":"e5002","article-title":"De novo myasthenia gravis induced by Atezolizumab in a patient with urothelial carcinoma","volume":"11","author":"Thakolwiboon","year":"2019","journal-title":"Cureus"},{"key":"2025072811472653000_2.1.e000028.3","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.355","article-title":"Pembrolizumab-induced myasthenia gravis with myositis in a patient with lung cancer","volume":"6","author":"Hibino","year":"2018","journal-title":"Respirol Case Rep"},{"key":"2025072811472653000_2.1.e000028.4","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000007350","article-title":"Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma","volume":"96","author":"Chen","year":"2017","journal-title":"Medicine"},{"key":"2025072811472653000_2.1.e000028.5","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2018.00150","article-title":"Myasthenia gravis induced by ipilimumab in a patient with metastatic melanoma","volume":"9","author":"Montes","year":"2018","journal-title":"Front Neurol"},{"key":"2025072811472653000_2.1.e000028.6","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0774-y"},{"key":"2025072811472653000_2.1.e000028.7","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-019-1416-1","article-title":"Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report","volume":"19","author":"Kamo","year":"2019","journal-title":"BMC Neurol"},{"key":"2025072811472653000_2.1.e000028.8","doi-asserted-by":"crossref","DOI":"10.1007\/s11910-018-0878-7","article-title":"Neuromuscular complications of programmed cell death-1 (PD-1) inhibitors","volume":"18","author":"Kao","year":"2018","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2025072811472653000_2.1.e000028.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481"},{"key":"2025072811472653000_2.1.e000028.10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00544-6"},{"key":"2025072811472653000_2.1.e000028.11","doi-asserted-by":"crossref","unstructured":"Youssef M , Woodman K . Neurologic complications of immune checkpoint inhibitors in cancer patients (P4.162). Neurology 2018;11.","DOI":"10.1212\/WNL.90.15_supplement.P4.162"},{"key":"2025072811472653000_2.1.e000028.12","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","article-title":"Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors","volume":"82","author":"Makarious","year":"2017","journal-title":"Eur J Cancer"},{"key":"2025072811472653000_2.1.e000028.13","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/CJI.0000000000000196","article-title":"Pd-1 inhibitor-associated myopathies: emerging immune-mediated myopathies","volume":"41","author":"Liewluck","year":"2018","journal-title":"J Immunother"},{"key":"2025072811472653000_2.1.e000028.14","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0152-y"}],"container-title":["BMJ Neurology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjno-2019-000028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T18:47:34Z","timestamp":1753728454000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurologyopen.bmj.com\/lookup\/doi\/10.1136\/bmjno-2019-000028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,3,19]]},"published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1136\/bmjno-2019-000028"],"URL":"https:\/\/doi.org\/10.1136\/bmjno-2019-000028","relation":{},"ISSN":["2632-6140"],"issn-type":[{"value":"2632-6140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3]]}}}